Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Completed 2Unknown 1Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Dermatologic 4

Conditions

Carcinoma, Hepatocellular 9Neoplasms 4Melanoma 4Breast Neoplasms 4Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Sarcoma 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycystic Ovary Syndrome 2Pleural Effusion, Malignant 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Anxiety Disorders 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Recurrence 1Rare Malignant Neoplasm 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphedema 1Locally Advanced Bladder Cancer 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Specimen Handling 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Melanoma × Pharmaceutical Preparations × Clear all
NCT06599619 2026-01-26

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

University of Pittsburgh

Recruiting
30 enrolled
Dermatologic

Dysplastic Nevus Syndrome, Melanoma, Hereditary Sensory and Autonomic Neuropathies

NCT01973322 2025-01-09

ABSIDE

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed
34 enrolled
Dermatologic

Melanoma

NCT00203879 2013-09-05

Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma

University of Chicago

Phase 2 Completed
19 enrolled
Dermatologic

Melanoma

NCT00226473 2006-06-21

Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma

Dermatologic Cooperative Oncology Group

Phase 4 Unknown
200 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡